

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

WYETH

2. Address:

1667 K STREET NW, #1270, WASHINGTON, DC 20006

3. Principal place of business (if different from line 2):

4. Contact Name: LEO C. JARDOT

Telephone: 2026598320

E-mail (optional): jardot@wyeth.com

Senate ID #: 2558-12

House ID #:

7. Client Name: Self

TYPE OF REPORT

8. Year 2006 Midyear (January 1 - June 30): **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report: => Termination Date: _____ 11. No Lobbying Activity:

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more: => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more: => Expenses (nearest \$20,000): 1,986,000.00

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only
 Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
 Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: WYETH Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: BUD (one per page)

16. Specific lobbying issues:

Pharmaceutical drug importation H.R. 5384 - Agriculture and Related Agencies Appropriation/Food and Drug Administration HJ Res.102 - Continuing Appropriations Resolutions

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
SENATE
White House Office

18. Name of each individual who acted as a lobbyist in this issue area:

Name: JARDOY, LEO C.

Covered Official Position (if applicable): VICE PRESIDENT, GOVERNMENT RELATIONS

Name: KAYE, BRONWEN

Covered Official Position (if applicable): SENIOR DIRECTOR, GOVERNMENT RELATIONS

Name: RABINOWITZ, JULIE

Covered Official Position (if applicable): SENIOR DIRECTOR AND COUNSEL, GVT RELATIONS

Name: RIEMER, ANGELA

Covered Official Position (if applicable): SENIOR DIRECTOR, GOVERNMENT RELATIONS

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: WYETH Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CPT (one per page)

16. Specific lobbying issues:

Monitor U.S. trade policies relating to intellectual property protection under the WTO TRIPS agreement H.R. 5418 H.R. 2795

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

Natl Security Council (NSC)

Office of the Vice President of the United States

SENATE

State, Dept of (DOS)

U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area:

Name: JAR DOT, LEO C.

Covered Official Position (if applicable): VICE PRESIDENT, GOVERNMENT RELATIONS

Name: KAYE, BRONWEN

Covered Official Position (if applicable): SENIOR DIRECTOR, GOVERNMENT RELATIONS

Name: RABINOWITZ, JULIE

Covered Official Position (if applicable): SENIOR DIRECTOR & COUNSEL, GOVT RELATIONS

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: WYETH Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: CSP (one per page)

16. Specific lobbying issues:

Tort and product liability reform; Medical malpractice reform FDA reform proposals; Pseudoephedrine; H.R. 5280 - Dextromethorphan

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: JARDOT, LEO C.

Covered Official Position (if applicable): VICE PRESIDENT, GOVERNMENT RELATIONS

Name: KAYE, BRONWEN

Covered Official Position (if applicable): SENIOR DIRECTOR, GOVERNMENT RELATIONS

Name: RABINOWITZ, JULIE

Covered Official Position (if applicable): SENIOR DIRECTOR & COUNSEL, GOVT RELATIONS

Name: RIEMER, ANGELA

Covered Official Position (if applicable): SENIOR DIRECTOR, GOVERNMENT RELATIONS

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: WYETH Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

Issues relating to support of Office of Women's Health and Public Education Initiatives Childhood immunizations Dietary supplement issues FDA reform issues S.3 Protecting America in the War on Terror H.R. 650 Vaccines Act of 2005 H.R. 2863 Department of Defense Appropriations Act of 2006 Medicare reimbursement for certain drugs Importation Bioterrorism Direct to consumer advertising S.334 Pharmaceutical Market Access and Drug Safety Act of 2005 Implementation issues concerning P.L. 108-173 - The Medicare Prescription Drug, Improvement and Modernization Act of 2003 Issues concerning Medicaid in the Concurrent Resolution on the Budget - Fiscal Year 2006 Medical coverage of self-injectable biologicals Issues related to vaccine injury compensation program Follow developments within the Bush Administration relating to global health policies concerning U.S. government participation in WHO and UN health initiatives; international public health issues; U.S. sanctions policies Issues relating to Medicaid reimbursement for drugs/biologics in Title VI of S.1932-the Deficit Reduction Act of 2005 Pandemic Influenza S.3678 S. Con. Res 83, "Concurrent Resolution on the Budget for Fiscal Year 2007."; issues relating to amending the Medicare Prescription Drug and Modernization Act of 2003 (P.L.108-173) to authorize the Secretary of HHS to negotiate drug prices for the Part D Medicare prescription drug benefit. H.R. 5384, "Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act of 2007," issues related to the importation of prescription drugs. Issues related to vaccine injury compensation program S.843 - The Combating Autism Act of 2005 H.R. 4939 - Supplemental Appropriations H.R. 5441 - FY 2007 Homeland Security Appropriations Drug Compounding H.R. 5122, S.2767 - Department of Defense Authorizations S.3807 - Enhancing Drug Safety and Innovation Act of 2006 Alzheimer's care HR 5211; S.2767 - Department of Defense Authorizations H.R. 5384 - "Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act of 2007," issues related to the importation of prescription drugs; issues related to the Vaccine Injury Compensation Program Issues related to hormone therapy and the use of HT and BHRT products. Vaccine Injury Compensation Program Follow developments within the Bush Administration relating to global health policies concerning U.S. government participation in WHO and UN health initiatives; international public health issues; U.S. sanctions policies

17. House(s) of Congress and Federal agencies contacted:

Executive Office of the President (EOP)
Food & Drug Administration (FDA)
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
Justice, Dept of (DOJ)
Nat'l Security Council (NSC)
SENATE
State, Dept of (DOS)
Treasury, Dept of
U.S. Trade Representative (USTR)
White House Office

18. Name of each individual who acted as a lobbyist in this issue area:

Name: JARDOT, LEO C.

Covered Official Position (if applicable): VICE PRESIDENT, GOVERNMENT RELATIONS

Name: KAYE, BRONWEN

Covered Official Position (if applicable): SENIOR DIRECTOR, GOVERNMENT RELATIONS

Name: RABINOWITZ, JULIE

Covered Official Position (if applicable): SENIOR DIRECTOR & COUNSEL, GOVT RELATIONS

Name: RIEMER, ANGELA

Covered Official Position (if applicable): SENIOR DIRECTOR, GOVERNMENT RELATIONS

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: WYETH Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

S.109/H.R. 328 - Pharmaceutical Market Access Act Implementation Issues concerning P.L. 108-173 - the Medicare Prescription Drug, Improvement and Modernization Act of 2003 Issues concerning Medicaid in the Concurrent Resolution on the Budget - Fiscal Year 2006 Medicare coverage of pharmaceuticals, Medicare Part D Issues relating to Medicaid reimbursement for drugs/biologics in Title VI of S.1932-the Deficit Reduction Act of 2005 Pediatric Exclusivity Prescription drug user fees; Methamphetamines Vaccines Non-Interference H.R. 4939, Supplemental Appropriations H.R. 6111 - Tax Relief and Health Care Act of 2006 Pharmaceutical reimbursement rates Medicare reform; Vaccines; Importation; Bioterrorism; Direct to consumer advertising S.975-Project Bioshield II Acts

17. House(s) of Congress and Federal agencies contacted:

Executive Office of the President (EOP)
HOUSE OF REPRESENTATIVES
Health & Human Services, Dept of (HHS)
SENATE
White House Office

18. Name of each individual who acted as a lobbyist in this issue area:

Name: JARDOT, LEO C.

Covered Official Position (if applicable): VICE PRESIDENT, GOVERNMENT RELATIONS

Name: KAYE, BRONWEN

Covered Official Position (if applicable): SENIOR DIRECTOR, GOVERNMENT RELATIONS

Name: RABINOWITZ, JULIE

Covered Official Position (if applicable): SENIOR DIRECTOR & COUNSEL, GOVT RELATIONS

Name: RIEMER, ANGELA

Covered Official Position (if applicable): SENIOR DIRECTOR, GOVERNMENT RELATIONS

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: WYETH Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TAX (one per page)

16. Specific lobbying issues:

Puerto Rico Tax Incentives; Taxation of International Operations of U.S. corporations generally R&D Tax Credit; H.R. 6111

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: JARDOT, LEO C.

Covered Official Position (if applicable): VICE PRESIDENT, GOVERNMENT RELATIONS

Name: RABINOWITZ, JULIE

Covered Official Position (if applicable): SENIOR DIRECTOR & COUNSEL, GOVT RELATIONS

Name: RIEMER, ANGELA

Covered Official Position (if applicable): SENIOR DIRECTOR, GOVERNMENT RELATIONS

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: WYETH Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TOR (one per page)

16. Specific lobbying issues:

Tort and product liability reform Medical malpractice reform; FDA reform proposals

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: JARDOT, LEO C.

Covered Official Position (if applicable): VICE PRESIDENT, GOVERNMENT RELATIONS

Name: KAYE, BRONWEN

Covered Official Position (if applicable): SENIOR DIRECTOR, GOVERNMENT RELATIONS

Name: RABINOWITZ, JULIE

Covered Official Position (if applicable): SENIOR DIRECTOR & COUNSEL, GOVT RELATIONS

Name: RIEMER, ANGELA

Covered Official Position (if applicable): SENIOR DIRECTOR, GOVERNMENT RELATIONS

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: WYETH Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TRD (one per page)

16. Specific lobbying issues:

Monitor U.S. trade policies relating to intellectual property protection under the WTO TRIPS agreement Importation of FDA-approved pharmaceuticals

17. House(s) of Congress and Federal agencies contacted:

18. Name of each individual who acted as a lobbyist in this issue area:

Name: JARDOT, LEO C.

Covered Official Position (if applicable): VICE PRESIDENT, GOVERNMENT RELATIONS

Name: KAYE, BRONWEN

Covered Official Position (if applicable): SENIOR DIRECTOR, GOVERNMENT RELATIONS

Name: RABINOWITZ, JULIE

Covered Official Position (if applicable): SENIOR DIRECTOR & COUNSEL, GVT RELATIONS

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Jan 08, 2008

Printed Name and Title: LEO C. JARDOT, VICE PRESIDENT, GOVERNMENT RELATION -

Registrant Name: WYETH Client Name: Self

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Jan 08, 2008

Printed Name and Title: -